Could Lab-Grown cells free diabetics from insulin shots?

NCT ID NCT07503028

ENROLLING_BY_INVITATION Disease control Sponsor: Celregen Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests lab-grown pancreatic islet cells (CRG-002) in 10 adults with type 1 or pancreatogenic diabetes who have severe low blood sugar episodes. The cells are infused into the liver or placed under the belly skin. The goal is to see if they are safe and can help the body make insulin, possibly reducing the need for injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lab-grown pancreatic islet cells (CRG-002)
What this could lead to: If it works, this could point toward a way to reduce or stop insulin injections for some people with type 1 diabetes.
What could go wrong: This is a very early, small trial (10 people) focused on safety. The cells may not work well, could be rejected, or might require lifelong immune-suppressing drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATOGENIC DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATOGENIC DIABETES MELLITUS T1DM - TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

The First Affiliated Hospital of Anhui Medicaluniversity

Hefei, Anhui, 230022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.